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BACKGROUND: Polyphenol-rich foods such as pomegranate, green tea, broccoli and turmeric have demonstrated anti-neoplastic
effects in laboratory models involving angiogenesis, apoptosis and proliferation. Although some have been investigated in small,
phase II studies, this combination has never been evaluated within an adequately powered randomised controlled trial.
METHODS: In total, 199 men, average age 74 years, with localised prostate cancer, 60% managed with primary active surveillance
(AS) or 40% with watchful waiting (WW) following previous interventions, were randomised (2:1) to receive an oral capsule
containing a blend of pomegranate, green tea, broccoli and turmeric, or an identical placebo for 6 months.
RESULTS: The median rise in PSA in the food supplement group (FSG) was 14.7% (95% conﬁdence intervals (CIs) 3.4–36.7%), as
opposed to 78.5% in the placebo group (PG) (95% CI 48.1–115.5%), difference 63.8% (P¼ 0.0008). In all, 8.2% of men in the FSG and
27.7% in the PG opted to leave surveillance at the end of the intervention (w2 P¼ 0.014). There were no signiﬁcant differences
within the predetermined subgroups of age, Gleason grade, treatment category or body mass index. There were no differences in
cholesterol, blood pressure, blood sugar, C-reactive protein or adverse events.
CONCLUSIONS: This study found a signiﬁcant short-term, favourable effect on the percentage rise in PSA in men managed with AS and
WW following ingestion of this well-tolerated, speciﬁc blend of concentrated foods. Its inﬂuence on decision-making suggests that this
intervention is clinically meaningful, but further trials will evaluate longer term clinical effects, and other makers of disease progression.
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INTRODUCTION
Diets deﬁcient in polyphenols and other natural plant-based
phytochemicals found in herbs, spices, fruit, teas, colourful
vegetables and other healthy plant-based foods, have been linked
with higher risks of cancer particularly breast,1,2 pancreas,3 ovary,4
skin,5 prostate,6,7 bowel8 and oesophagus.9
The protective beneﬁts of polyphenols, however, do not to stop
after a diagnosis of cancer. Breast cancer survivors taking higher
levels of fruit and vegetables had a lower recurrence10 and those
with a higher dietary intake of lignans, isoﬂavones, ﬂavanones
within soy-rich foods or green tea had a lower risk of breast cancer
death.11–13 Individuals with skin cancer who had higher leafy,
green vegetable intake had a lower rate of new cancer formation.5
Men adopting healthy diets after prostate cancer were shown to
have slower PSA progression.14,15
The potential beneﬁts of concentrating foods into a pill has
been the subject of extentive evaluation. Up to now, research has
focused on supplements containing speciﬁc, extracted chemicals
believed to be the anti-cancer candidates and although some
studies have shown beneﬁts,16–18 most have not or were actually
linked to an increased risk of cancer. For example, the two vitamin
A and E studies increased the risk of lung cancer19,20 and an
Australian study linked a similar supplement intake with more
subsequent skin cancers.5 Long-term folate supplementation after
myocardial infarct resulted in a higher cancer risk.21 A supplement
containing vitamin C, copper and manganese did not slow PSA
progression;15 the selenium and vitamin E cancer prevention trial
(SELECT) study showed an increased prostate cancer incidence
following long-term intake of vitamin E and selenium22 as did men
in the Health Professionals Study, who took zinc.23 Despite some
initial encouragement from cohort and small prospective studies,
lycopene, saw palmetto or genistein extracts evaluated within
more scientiﬁcally robust analyses did not demonstrate a beneﬁt
for either prostate cancer, benign prostatic hypertrophy or other
malignancies.1,6,18,24–26
As a consequence of these data, scientiﬁc attention has been
turning towards the evaluation of concentrated polyphenol-rich
whole food supplements, rather than extracted chemicals, as
convenient ways to boost poor diets or further enhance already
adequate diets. There are some laboratory and phase II studies to
support their further evaluation and hence the rationale for this
study. Men with prostate cancer, managed with active surveillance
(AS) or watchful waiting (WW) for a PSA relapse after radical
treatments, were selected as an ideal cohort to evaluate a lifestyle
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intervention as they have a useful serum marker of their
disease, PSA, and medical interventions are often not indicated
initially.15
Rationale for the ingredients of this interventional food
supplement
Pomegranate, rich in ellagic acid, has been shown in in vitro
studies to inhibit proliferation, markers of migration, induce
apoptosis and cell adhesion in breast and prostate cancer cell
lines.27 In humans, a phase II study reported a prolongation of PSA
doubling following pomegranate juice consumption and markers
of oxidative stress improved.28 A further phase II study, gave men
pomegranate seed extract with similar effects.29 Its inﬂuence was
not felt to be via hormonal route as it affected both androgen-
sensitive and -resistant human prostate cancer cells, and one of
the clinical studies showed no change in testosterone levels
following regular intake.25,30–34
Green tea, rich in epigallocatechin gallate, has been shown to
block ornithine decarboxylase, an enzyme which signals cells to
proliferate faster and bypass apoptosis.35–37 It has also been
reported to reduce several growth factors which promote breast
and prostate cancer cell line growth, block de-differentiation and
angiogenesis.38 Men given an extract of tea illustrated a signiﬁcant
reduction in the levels of several growth factors that promote
cancer, as well as a beneﬁcial effect on PSA.35
Broccoli, rich in isothiocyanate and its metabolite sulphora-
phane, has been shown to inhibit growth and promote apoptosis
in cancer cells.39 In humans, a study found that regular broccoli
intake downregulated cancer genes linked to cancer promotion
and up-regulated genes link to cancer suppression.5,7,39,40
Curcumin, which gives turmeric its yellow colour, has been
shown to slow prostate cancer cell growth, increase apoptosis,
reduce markers of invasion and migration of cells.41–44 It has been
shown to inhibit tyrosine kinase activity of the epidermal growth
factor receptor,45 have cyco-oxidase-I-mediated anti-inﬂammatory
properties46 and halt the growth of stem cells that give rise to
breast cancer without inﬂuencing normal breast cells.46
Finally, all four ingredients also have some anti-oxidant proper-
ties that are thought to protect the DNA against oxidative damage
from ingested or environmental carcinogens,36,37,47 although this
precise mechanism has not been conﬁrmed clinically.48
The rationale and hypothesis for selecting the ingredients of
this supplement were that as they originate different food sources
(fruit, herb, vegetable and leaf), each with their unique proﬁle and
concentration of polyphenols, their separate anti-cancer mechan-
isms, summarised above, could be synergistic49,50 yet at the same
time their variable composition would avoid over-consumption of
one particular phytochemical.25,30,32–34,41–44 The trial committee
determined the concentration of each ingredient based on the
amounts safely used within previous clinical studies.25,30,32–34,41–44
MATERIALS AND METHODS
This was a placebo-controlled, double-blind, randomised trial designed
with the aim of establishing whether supplementing the diet with a
polyphenol-rich, whole food supplement containing a blend of green tea,
pomegranate, broccoli and curcumin (turmeric) inﬂuenced the rate of PSA
progression, compared with placebo among men with prostate cancer
either managed with primary AS or WW, following a PSA relapse post-
radical treatments. The 203 participants originated from across the UK and
were all consented and randomised at The Primrose Oncology Unit,
Bedford Hospital, from a total of 208 reviewed for eligibility, between
November 2011 and July 2012. The intervention consisted of a tablet taken
three times a day containing:
 broccoli powder (Brassica oleracea) 100mg,
 turmeric powder (Curcuma longa) 100mg,
 pomegranate whole fruit powder (Punica granatum) 100mg,
 green tea 5:1 extract (Camellia sinensis) 20mg equivalent to 100mg of
green tea and
 bulking agent (di-calcium phosphate), anti-caking agents (modiﬁed maize-
based starch, maltodextrin and magnesium stearate) removed post trial.
The control group took a placebo containing identical bulking and anti-
caking agents with 10mg of watercress extract to provide an identical
colour and substance.
All participants were men with an average age of 74 years (range 53–89
years), with histologically conﬁrmed prostate cancer, 121 (60%) were being
managed with AS, and 78 (40%) managed with WW following previous
radical interventions and radical local salvage therapies had been excluded
(primary radiotherapy, 65; surgery followed by radiotherapy, 8; and
brachytherapy, 9). The baseline characteristics are summarised in Table 1.
Following written informed consent, men were randomised by
externally generated, numerically sequenced, opaque, tamper-proof
envelopes to the food supplement group (FSG) or placebo group (PG).
There was a 2:1 randomisation which resulted in 136 in the FSG and 67 in
the PG. Four men withdrew consent after initial randomisation and
proceeded to intervention before the 3-month consultation (two from
each group), had no further relevant PSA and as such could not be
included in an intention to treat analysis (Figure 1). At baseline, 3 months
and 6 months post intervention, PSA, full blood count, urea and
electrolytes, liver function proﬁle, blood glucose, fasting cholesterol,
C-reactive protein, body weight, height and blood pressure were
measured. Adverse and favourable events were recorded in the Case
Report Form according to the National Cancer Institute (NCI) common
toxicity grading scale.
Certiﬁcation and quality assurance
This trial was approved by the National Ethics Committee, was peer
reviewed by the National Cancer Research Institute (NCRI) Complementary
Therapies Research Committee and formally adopted by the National
Cancer Research Network (NCRN). The Medicines and Health Regulatory
Agency (MHRA) conﬁrmed that no MHRA licence was required as the
intervention was not classiﬁed as a medicinal product. The randomisation
process was outsourced and the trial methodology, collection and storage
of data were veriﬁed and independently audited by an external agency to
ensure adherence to European Good Clinical Practice. At the end of the
trial, data were externally audited for a second time to ensure that there
were no data inconsistencies or deviation from the trial design, before the
database was sealed and sent for blinded analysis by the statistician at
Cranﬁeld University. The UK manufacturers of the food supplement (Power
Health Products, York, UK) adhered to good manufacturing practice
guidelines and performed in-house analysis for authenticity and purity (the
manufacturing analysis certiﬁcates were presented to the reviewers of the
publication). The food supplement and placebo tablets were supplied to
the trials unit in tamper-proof, sealed containers. A batch of the
supplement has been securely stored by the trust secretary and can be
sent to any regulatory body at request.
Table 1. Summary of baseline characteristic in the randomly assigned
groups
Baseline characteristic FSG (134) PG (65)
Age (mean years) 71.8 76.4a
PSA (mean mg l 1) 6.5 6.5
Gleason gradep7 127 (95%) 57 (88%)
Gleason grade 47 7 (5%) 8 (12%)
Gleason grade mean (mg l 1) 6.5 6.2
BMI (mean kgm 2) 28.1 28.3
Cholesterol (mean mmol l 1) 4.87 4.72
BP (mean systolic/diastolic mmHg) 146/83 150/82
Serum glucose (mean mmol l 1) 5.15 5.30
C-reactive protein (mean mg l 1) 1.51 1.74
Abbreviations: BMI, body mass index; BP, blood pressure; FSG, food
supplement group; PG, placebo group.
The mean age in the PG was older by 4.4 years (t-test P¼ 0.013) so age was
included in the analysis of the percentage change in PSA as a covariate.
aRandomisation produced no statistical difference in the group character-
istics except for age.
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Statistical considerations
The patient representatives on the NCRI Development Committee felt that
a 2:1 randomisation would be more acceptable to participants. This
appeared to be a correct assertion because all but ﬁve eligible men invited
to enter this study agreed to be randomised. The PSA value used for the
ﬁnal analysis was pre-determined to be the 6-month value or the 3-month
value in the men who withdraw at this stage.
Statistical methods
The percentage change in PSA from baseline to ﬁnal measurement was
evaluated using an analysis of covariance (ANCOVA) which assessed the
effect of the FSG versus PG, as well as the predetermined subgroups of
Gleason grade, body mass index and treatment category. Age was
included as a covariate to adjust for any differences in age between
groups. The interactions between the effect of the FS and each of the other
categorical effects were also included in the analysis. To satisfy the
assumptions of this analysis, the change in PSA had to be transformed to
logarithms, P-values given in this section followed by ANCOVA are from
the F-value in this ANCOVA. All median values were back transformed from
this ANCOVA and therefore allow for the effect of any differences in other
subgroups or age.
The analysis of the number of men at the end of the trial with the same
or lower PSA was analysed using a w2 test with 1 degree of freedom. The
differences in toxicity measures between the two groups were tested using
an appropriate t-test (that is, with equal or unequal variances), and
transforming the measure if required to satisfy the assumptions of a t-test.
RESULTS
Primary end point
In the FSG, the mean PSA rose from 6.50 to 6.81 ug l 6 from
baseline to the end of the intervention, a median PSA percentage
rise of 14.7% (95% conﬁdence interval (CI)  3.4% to 36.7%). In
the PG, the mean PSA increased from 6.50 to 10.98 ug l 1, a
median percentage rise of 78.5% (95% CI 48.1–115.5%). The
median percentage PSA increased at a signiﬁcantly slower rate in
the FSG group compared with the PG (difference 63.8% ANCOVA,
P¼ 0.0008).
Secondary end point
The number of men with a PSA lower or the same value at trial
completion was 61 (46%) in the FSG as opposed to 9 (14%) in the
PG. This difference was statistically signiﬁcant (w2 value with 1
degree of freedom¼ 19.58, P¼ 0.000010).
Decisions to remain on AS or WW
Twenty-ﬁve men opted to leave AS or WW at 3 months (11 in the
FSG and 14 PG), and 4 after 6 months, 11 of 134 in the FSG (8.2%)
and 18 of 65 (27.7%) in the PG (this difference of 19.5% was
signiﬁcant w2 value with 1 degree of freedom, P¼ 0.014). The
reasons for opting out were multifactorial and at the discretion of
the physician and patient who were both blind to the intervention
arm but all had a rising PSA.
Predetermined subgroup analysis
A separate analysis of the cohort of men managed with AS
(n¼ 121) revealed that in the FSG the mean PSA dropped by
0.14% (95% CI  7.57 to 7.95), whereas in the PG it rose by 46.98%
(95% CI 28.51–68.31); difference 47.12% (ANVOCA, P¼ 0.001), see
Figure 2. A separate analysis of the cohort of men managed with
WW (n¼ 78) revealed that in the FSG the mean PSA rose by 8.78%
(95% CI  6.32 to 26.62), whereas in the PG it rose by 80.34%
Figure 1. Consort diagram highlighting the flow of patients through the National Cancer Research Network Pomi-T study.
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Figure 2. Median percentage rise in PSA between men taking the
food supplement versus placebo.
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(95% CI 50.54–116.55); difference 71.56% (ANVOCA, P¼ 0.001), see
Figure 3. This difference between the median percentage change
in PSA in either the AS or WW cohorts was not statistically
signiﬁcant (P¼ 0.805 ANCOVA) (Figure 4).
There was no statistical difference between the median
percentage PSA rise between men in the FSG or the PG as to
whether they were overweight (X25 kgm 2) or not (P¼ 0.564
ANCOVA). Although men with higher Gleason grade for the entire
cohort tended to progress at a faster rate, there was no difference
between the median percentage change in PSA between men in
the FSG or the PG whichever Gleason grade category they were
(P¼ 0.089 ANCOVA). There was a signiﬁcant effect of age on the
median percentage change in PSA for the entire cohort with older
men tending to progress at a slower rate (P¼ 0.0272 ANCOVA;
slope of log(MPC-PSA)¼ 0.0098, P¼ 0.0272). As there were more
older men randomised to the PG, age was included as a covariate
in the analysis so that the difference between the median
percentage change in PSA for FSG and PG was adjusted to the
mean age of the whole cohort, so that any effect on PSA between
FSG and PG would have been removed.
Other measures
There were no signiﬁcant differences at the beginning or the end
of the study between groups for cholesterol, blood pressure,
serum glucose or C-reactive protein. Compliance, measured by
counting remaining tablets in returned pots, was excellent and
similar at 98.4% in the PG and 96.5% in the FSG. Sex hormones
were not a predetermined analysis, as the ingredients were
speciﬁcally chosen not to have phytoestrogenic properties but
were measured in 64 men who had been taking the supplement
for at least 3 months or more. Three of these men (5.5%) had
testosterone levels below our laboratory normal range. The
average testosterone (13.4 nmol l 1) was within the normal range
as were the other sex hormones: follicle stimulating hormone,
9.2 iu l 1; luteinizing hormone, 7.4 iu l 1; sex hormone binding
globulin, 41.4 nmol l 1; and free androgen index, 24.3%. Magnetic
resonance images (MRI) of the prostate were also not included at
speciﬁc time points in the trial protocol but a total of 74 of the 121
men on AS, were taken as part of their routine management
clinical protocol. All these scans, in addition to their original report,
were scrutinised within our multidisciplinary team meetings.
Twelve (16%) men had radiologically progressive disease and in
these men the average PSA rose from 7.65 to 8.67 ug l 1. Eight
(11%) had radiological regression and in these the average PSA
dropped from 7.2 to 4.1 ug l 1. No man in the FSG had
radiological progression with a stable PSA but one man (1.3%)
not taking the FS had radiological progression with a falling PSA.
Although these ﬁgures were not subjected to statistical analysis as
MRI was not a predetermined end point but they do give some
reassurance that PSA change is linked to underlying disease
status.
Adverse events
There were 34 (24%) men who recorded adverse events (any NCI
score) in the FSG group and 23 (34%) in the PG. These differences
were not statistically signiﬁcant (w2 value with 1 degree of
freedom¼ 2.2, P¼ 0.14). There were no grade X3 toxicities, but
one man in the FSG group had grade 2 diarrhoea. Gastrointestinal
events, considered separately, occurred in 21 (15.5%) in the FSG
group as opposed to 5 (7.5%) in the PG, but this difference
was not statistically signiﬁcant (w2 value with 1 degree of
freedom¼ 2.24, P¼ 0.11). No man in either group reported central
nervous system symptoms, such as agitation, insomnia or tremors,
none of the 30 men on warfarin reported any unexpected change
in the international normalized ratio, nor did the 43 men taking
ramipril report an unexpected change in their blood pressure.
Positive events
There were 16 (12%) men who recorded positive events (mainly
improved bowel and urinary function) in the FSG, and 3 (4.6%) in
the PG. These differences were not statistically signiﬁcant (w2 value
with 1 degree of freedom¼ 2.67, P¼ 0.10) (Table 2).
DISCUSSION
This study demonstrated a signiﬁcant effect on the rate of PSA
progression among men with prostate cancer, randomised to take
this nutritional supplement compared with placebo. The differ-
ence was large, the patient characteristics were well-balanced and
the trial had sufﬁcient numbers to ensure adequate statistical
power. However, there are some caveats with the trial design to
consider and discuss.
The ﬁrst caveat was the relatively short, 6 months, duration of
the intervention which although enough time to detect an early
difference, as men are often managed with surveillance for many
years, a longer design would exclude the possibility that this effect
was short lived. On the other hand, a longer study would have
been beyond the funding constraints of this non-commercial
Key: FS = Food supplement, ANCOVA = Analysis of covariance,
= 95% confidence intervals
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Figure 3. Subgroup analysis: median percentage change in PSA for
the 121 men managed with active surveillance (AS).
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study. Furthermore, a trial designed to take a potential placebo for
longer would have been a less attractive option for men, so the
rapid recruitment achieved in this study would have been less
likely.
The second caveat was that the main end point relied on PSA
measurement, without other formal indicators of disease progres-
sion including MRI or prostate biopsies which are now becoming
routine in the management of men on AS. Although biopsy would
have enhanced scientiﬁc competence, not all men currently
consent a repeat intervention and hence this inclusion would have
reduced the rate of recruitment, increased complexity. The cost of
including MRI before and after the trial period would also have
been prohibitive for the level of sponsorship available but
fortunately, images were taken as part of their routine manage-
ment in over half of the men in the AS group. It is of some
reassurance, that PSA reﬂected underlying disease status as the
percentage change in PSA was 10-fold lower in the men with
disease shrinking on MRI compared with disease progression and
no man taking the food supplement had disease progression with
a stable PSA. All men choosing to continue to supplement after
the trial period will now receive annual MRI’s this data will subject
to a future publication.
Another issue with the trial design was that the cohort included
men both on primary AS and those experiencing a PSA relapse
after radical treatments, deemed not eligible for salvage local
therapies. The design committee believe that this was not a
negative caveat as there were appropriate reasons for this choice.
First, in our experience, this is precisely the group of men who are
most interested in lifestyle strategies15 and a trial cohort should,
where possible, reﬂect the wider population considering the study
intervention. Both groups of men are similar as they have viable
prostate cancer, and are not receiving other systemic therapies.
Both groups have serum PSA being monitored as part of their
routine clinical management. Previous nutritional studies have
also included both groups.15,17,26 To support this rationale, in
this study, there was no statistical difference in the effect on
PSA between both cohorts, suggesting a similar effect of
polyphenol-rich foods, regardless of whether patients had
received radiotherapy or not.
Despite these caveats, although PSA has its short falls, men
managed with AS or WW are greatly concerned with their serum
levels and a rise is often a trigger for a change in their
management.31 This was borne out in the trial, as 29 men opted
for to leave AS or WW during or at the end of the study when their
PSA rose, twice the percentage in the PG than the FSG. This
difference, as well as achieving strong statistical signiﬁcance,
suggests a clinically meaningful effect. Notwithstanding avoidance
of the inevitable toxicities of androgen deprivation therapy, with
over a 10-fold difference in price between this food supplement
and androgen deprivation therapy, a future trial should include a
cost-effectiveness analysis in order to determine the magnitude of
potential savings for healthcare providers.15
As well as price, other attractive features of this supplement
were its tolerance and safety. There were no overall statistically
signiﬁcant difference in symptoms compared with placebo, although
more men in the supplement group experienced non-signiﬁcant
bloating or diarrhoea, but almost as many reported beneﬁcial
effects including improved digestion and urinary symptoms. The
trend towards better urinary symptoms is worthy of future scrutiny
in the next study, especially as previous studies have linked
turmeric with improved symptoms of prostatitis presumably via its
anti-inﬂammatory properties.41,46 One of the ingredients of the
supplement, pomegranate, has been cited to be a weak inhibitor
of cytochrome P450 but, reassuringly, the quantities used in this
study resulted in no unexpected changes in blood pressure or
international normalized ratio levels, which could have related to
interference of the metabolism of ramipril or warfarin.
Although, these ingredients have previously demonstrated
fundamental effects on cancer progression in laboratory studies
including markers of angiogenesis, metastasis, adhesion and
apoptotis,25,30,32–34,41–44 our next trial will explore these mech-
anisms in more detail building upon the translational designs
instigated by previous researchers.14 Furthermore, although these
ingredients were speciﬁcally selected not to have phytoestrogenic
properties and the average sex hormone levels were reassuringly
normal in the subgroup who had them measured, the next trial
will also explore the physiological effects on participants in more
detail, including serum testosterone and markers of oxidative
stress.2,34
In conclusion, this statistically valid double-blind randomised
controlled trial has demonstrated a signiﬁcant short-term effect on
PSA and is food for thought for men living with prostate cancer,
50–70% of whom are reported to have taken ‘over-the-counter’
supplements.47 The favourable effect on PSA progression was
signiﬁcant both in men on primary AS and those experiencing a
PSA relapse after radiotherapy. This low cost food supplement was
well-tolerated and also inﬂuenced clinically relevant decisions, as
to whether to switch to interventions with more toxicity. Although
these results do not prove a long-term effect, they have provided
signiﬁcant encouragement to design a major study with more
Table 2. Summary of the adverse and positive events
FSG
(% of 134)
PG
(% of 65)
Difference %
(significance)
Adverse gastro-intestinal events
Loose bowels 6 (4.5%) 0 (0%) 4.5 (ns)
Diarrhoea (grade 1) 2 (1.5%) 0 (0%) 1.5 (ns)
Diarrhoea (grade 2) 2 (1.5%) 1 (1.5%) 0 (ns)
Diarrhoea (grade
X3)
0 (0%) 0 (0%) 0 (ns)
Constipation 2 (1.5%) 0 (0%) 1.5 (ns)
Flatulence 5 (3.6%) 0 (0%) 3.6 (ns)
Rectal bleeding 0 (0%) 1 (1.5%) 1.5 (ns)
Nausea 0 (0%) 1 (1.5%) 1.5 (ns)
Bloating 4 (3%) 2 (3%) 0 (ns)
All GI adverse
events
21 (15.5%) 5 (7.5%) 8 (ns)
Other adverse events
Gout exacerbation 2 (1.5%) 1 (1.5%) 0 (ns)
Worsening urinary
flow
2 (1.5%) 2 (3%) 1.5 (ns)
Worsening renal
function
2 (1.5%) 0 (0%) 1.5 (ns)
Weight loss 0 (0%) 2 (3%) 3 (ns)
Non-specific
‘feeling unwell’
2 (1.5%) 4 (6%) 4.5 (ns)
Miscellaneous
unrelated
5 (3.6%) 9 (13.4%) 9.8 (ns)
All adverse events 34 (24%) 23 (34%) 10 (ns)
Positive events
Improved erectile
function
1 (0.75%) 0 (0%) 0.75 (ns)
Improve urinary
flow
4 (3%) 1 (1.5%) 1.5 (ns)
Reduced prostatic
discomfort
1 (0.75%) 0 (0%) 0.75 (ns)
All positive
prostatic symptoms
6 (4.5%) 1 (1.5%) 3 (ns)
Improved bowel
function
8 (6%) 0 (0%) 6 (ns)
Improved well
being
2 (1.5%) 2 (3%) 0 (ns)
All positive event 16 (12%) 3 (4.5%) 7.5 (ns)
Abbreviation: FSG, food supplement group; GI, gastrointestinal; ns, non-
significant difference; PG, placebo group.
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comprehensive physiological, radiological and translational
laboratory end points, in order to get a deeper understanding
of the evidence of beneﬁt and role for these complex and readily
available foods.
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